|
|
Shrimp anti-lipopolysaccharide factor |
|
Vaxjo ID |
301 |
|
Vaccine Adjuvant Name |
Shrimp anti-lipopolysaccharide factor |
|
Adjuvant VO ID |
VO_0005702
|
|
Description |
Shrimp anti-lipopolysaccharide factor (SALF) is an antimicrobial peptide with reported anticancer activities, including suppression of tumor progression. |
|
Stage of Development |
Research |
|
Host Species for Testing |
Mouse |
|
Structure |
Antimicrobial peptide |
|
Preparation |
The paper describes the preparation of a vaccine comprising SALF in conjunction with inactivated murine bladder carcinoma cells (MBT-2) lysate, but not the preparation of SALF itself. |
|
Dosage |
The paper states that immunization of 7, 14, and 21-day-old mice was performed |
|
Function |
Type: microbial derivative vaccine adjuvant. Induces Th1-biased immune profile. Our study shows that SALF added to cell culture media inhibits growth progression of MBT-2, and that SALF together with inactivated MBT-2 lysate elevates the level of inflammasome activity, and modulates the levels of IL-1, MCP-1, IL-6, IL-12, and TNF in mouse macrophages. |
| References |
Huang et al., 2015: Huang HN, Rajanbabu V, Pan CY, Chan YL, Chen JY, Wu CJ. Enhanced Control of Bladder-Associated Tumors Using Shrimp Anti-Lipopolysaccharide Factor (SALF) Antimicrobial Peptide as a Cancer Vaccine Adjuvant in Mice. Marine drugs. 2015; 13(5); 3241-3258. [PubMed: 26006716].
|
|
